Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment

European Journal of Radiology

Volumn 83, Issue 9, 2014, Pages 1631-1638

  Bufi, Enida ^a   Belli, Paolo ^a   Di Matteo, Marialuisa ^a   Terribile, Daniela ^b   Franceschini, Gianluca ^b   Nardone, Luigia ^a   Petrone, Gianluigi ^a   Bonomo, Lorenzo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Breast cancer; Complete Pathological response; Diffusion weighted imaging; Neoadjuvant chemotherapy; RECIST classification; Tumor subtype

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FAMILY HISTORY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LUMINAL BREAST CANCER; MAJOR CLINICAL STUDY; MENOPAUSE; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARITY; PHENOTYPE; PHENOTYPIC VARIATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT THERAPY; BREAST NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84906311571     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2014.05.002     Document Type: Article

References (30)

1. F. Sardanelli, C. Boetes, and B. Borisch et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group Eur J Cancer 46 2010 1296 1316
2. M.L. Marinovich, N. Houssami, and P. Macaskill et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy J Natl Cancer Inst 2013
3. M.B.I. Lobbes, R. Prevos, and M. Smidt et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review Insights Imaging 2013
4. W.A. Berg, L. Gutierrez, and M.S. NessAiver et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer Radiology 233 2004 830 849
5. D. Cowen, G. Houvenaeghel, and V. Bardou et al. Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer Int J Radiat Oncol Biol Phys 47 2000 305 312
6. P. Belli, M. Costantini, and C. Malaspina et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy Clin Radiol 61 2006 946 953
7. H.J. Kim, Y.-H. Im, and B.-K. Han et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI Acta Oncol 46 2007 996 1003
8. F. Denis, A.V. Desbiez-Bourcier, C. Chapiron, F. Arbion, G. Body, and L. Brunereau Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer Eur J Surg Oncol 30 2004 1069 1076
9. S.C. Partridge, J.E. Gibbs, Y. Lu, L.J. Esserman, D. Sudilovsky, and N.M. Hylton Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy AJR Am J Roentgenol 179 2002 1193 1199
10. L.A. Carey, E.C. Dees, and L. Sawyer et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2007 2329 2334
11. H. Mersin, E. Yildirim, U. Berberoglu, and K. Gülben The prognostic importance of triple negative breast carcinoma Breast 17 2008 341 346
12. J.H. Chen, B. Feig, and B. Feig et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy Cancer 112 2008 17 26
13. C.E. Loo, M.E. Straver, and S. Rodenhuis et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype J Clin Oncol 29 2011 660 666
14. K.P. McGuire, J. Toro-Burguete, H. Dang, J. Young, A. Soran, and M. Zuley MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 18 2011 3149 3154
15. J.-H. Chen, S. Bahri, and R.S. Mehta et al. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging Radiology 261 2011 735 743
16. A. Kuzucan, J.-H. Chen, and S. Bahri et al. Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile Clin Breast Cancer 12 2012 110 118
17. E.L. Persijn van Meerten, H. Gelderblom, and J.L. Bloem RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline Eur Radiol 20 2009 1456 1467
18. P. Belli, M. Costantini, and C. Ierardi et al. Diffusion-weighted imaging in evaluating the response to neoadjuvant breast cancer treatment Breast J 17 2011 610 619
19. P. Belli, M. Costantini, and E. Bufi et al. Diffusion-weighted imaging in breast lesion evaluation Radiol Med 115 2010 51 69
20. A.M. Mandard, F. Dalibard, and J.C. Mandard et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer 73 1994 2680 2686
21. R. Croshaw, H. Shapiro-Wright, E. Svensson, K. Erb, and T. Julian Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients Ann Surg Oncol 18 2011 3160 3163
22. R. Woodhams, S. Kakita, and H. Hata et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging - comparison with contrast-enhanced MR imaging and pathologic findings Radiology 254 2010 357 366
23. H.J. Shin, H.-M. Baek, and J.-H. Ahn et al. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS NMR Biomed 25 2012 1349 1359
24. E. Bufi, P. Belli, and M. Costantini et al. MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer Br J Radiol 85 2012 e995 e1103
25. M.E. Straver, C.E. Loo, and E.J.T. Rutgers et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy Ann Surg 251 2010 701 707
26. Y. Hayashi, H. Takei, and S. Nozu et al. Analysis of complete response by MRI following neoadjuvant chemotherapy predicts pathological tumor responses differently for molecular subtypes of breast cancer Oncol Lett 5 2013 83 89
27. C. Hayes, A.R. Padhani, and M.O. Leach Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging NMR Biomed 15 2002 154 163
28. R.A. Kauppinen Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy NMR Biomed 15 2002 6 17
29. C. Creighton The molecular profile of Luminal B breast cancer Biol Targets Ther 6 2012 289 297
30. M. Ono, H. Tsuda, and M. Yunokawa et al. Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers Breast Cancer 2013 [Epub ahead of print]